SE0002190926
© Globe Newswire
17.11.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition publishes data on the benefits of early treatment with golexanolone in Parkinson’s disease
News Preview
STOCKHOLM – November 17, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has published data in the scientific journal Neuropharmacology, showing sustained benefits of early treatment with golexanolone in a Parkinson's disease model. The data show that golexanolone may delay the...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2025
KDEV
LISTED
STO
Interim Report - January-September 2025
News Preview
STOCKHOLM – 14 November 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-September 2025. The full report is available on the Company's website....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia
News Preview
STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in Q4 2025, in line...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
03.11.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company BOOST Pharma raises SEK 34 million through directed share issue to Sound Bioventures
News Preview
Stockholm, Sweden – November 3, 2025 – Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has raised a SEK 34 million investment structured as a tranched convertible loan from Sound Bioventures.The investment supports continued clinical development of BT-101, a pioneering stem cell-based thera...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
31.10.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company BOOST Pharma presents positive long-term data for its cell-based treatment of Osteogenesis imperfecta
News Preview
STOCKHOLM, SWEDEN, October 31, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented new long-term data from the BOOSTB4 phase 1/2 trial with the company’s cell therapy BT-101 targeting the rare bone disease Osteogenesis imperfecta. The new results comprise two-year follow-up...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
KDEV
LISTED
STO
Karolinska Development invests SEK 7.5 million to support BOOST Pharma’s continued development of BT-101 towards Phase 3
News Preview
Stockholm, Sweden – October 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that it has exercised its pro rata participation of SEK 7.5 million in BOOST Pharma’s latest financing. In total, BOOST Pharma’s financing, structured as a convertible loan, brings SEK 15 million to the company. The investment supports the conti...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company SVF Vaccines presents positive data from a preclinical study of SVF-001 in chronic hepatitis B and D
News Preview
STOCKHOLM, Sweden, October 24, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented positive results from a preclinical study of its immunotherapy SVF-001 targeting chronic hepatitis B and D at the Molecular Biology of HBV meeting in Berlin and the DeltaCure meeting in Hannover....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain
News Preview
STOCKHOLM, SWEDEN – October 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company PharmNovo has received approval from the Spanish regulatory authorities to initiate a phase 2a clinical trial of its drug candidate, PN6047, being developed as a treatment for neuropathic pain. The trial will be conduct...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor
News Preview
STOCKHOLM, SWEDEN – October 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has been granted a patent in the US protecting its drug candidate tafoxiparin for its main target indication, priming of labor. The patent will serve as a key asset as Dilafor advances into phase 3 clinical deve...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC01
News Preview
STOCKHOLM, SWEDEN September 16, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed enrollment in the phase 2a part of its clinical study GOAL-HF1. The ongoing study evaluates AnaCardio’s drug candidate AC01 in patients with heart failure and reduced ejection fraction, with res...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.09.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model
News Preview
STOCKHOLM – September 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented data showing that its drug candidate golexanolone provides sustained reversal of neuroinflammation in a Parkinson's disease model. The data, published in the scientific journal Frontiers in Im...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2025
KDEV
LISTED
STO
Interim Report - January-June 2025
News Preview
STOCKHOLM – 29 August 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-June 2025. The full report is available on the Company's website....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
14.07.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 24.6 for the ongoing clinical development of golexanolone
News Preview
STOCKHOLM, SWEDEN – July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 24.6 million through a convertible loan to be used for the ongoing clinical Phase 1b/2a study of golexanolone in primary biliary cholangitis. The convertible loan with attached share opti...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.07.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin
News Preview
STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part 1 of its ongoing clinical phase 2a study with sevuparin, which is being evaluated as a treatment for patients with chronic kidney disease with anemia....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.07.2025
KDEV
LISTED
STO
Karolinska Development receives update from Organon concerning OG-6219
News Preview
STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical d...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
KDEV
LISTED
STO
Karolinska Development divests shares in portfolio company OssDsign
News Preview
STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company’s liquidity. The divestments brings Karolinska Development a capital injection of approximately SEK 34.5 million....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million
News Preview
STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of SEK 28.3 million. The proceeds from the rights issue are intended to finance the continued development of the drug candidate sevuparin in chronic kidn...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.06.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets
News Preview
STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding procedure that brought the company approximately SEK 158 million. In connection with the directed share issue, the company announced an updated s...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.05.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study
News Preview
STOCKHOLM, SWEDEN – May 26, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has resumed the inclusion of patients to the clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. In March, Umecrine Cognition announced that the study had been halted d...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2025
KDEV
LISTED
STO
Karolinska Development’s Annual General Meeting 2025
News Preview
STOCKHOLM, SWEDEN – May 15, 2025. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 15, 2025. The shareholders have had the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the articles of association. Therefore, shareholders have had the...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 2025
News Preview
STOCKHOLM, SWEDEN – May 7, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will attend the EASL Congress 2025 in Amsterdam, May 7–10, to present validation and implementation data for the newly developed clinical scale for Primary Biliary Cholangitis, PBC.Umecrine Cognition is d...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.05.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation
News Preview
STOCKHOLM, SWEDEN – May 5, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been awarded a research grant by The Michael J. Fox Foundation (MJFF) amounting to USD 420,000. The grant will finance preclinical studies to evaluate the potential treatment effect of golexanolone in...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.04.2025
KDEV
LISTED
STO
Interim Report - January-March 2025
News Preview
STOCKHOLM – 30 April 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-March 2025. The full report is available on the Company's website....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO
News Preview
STOCKHOLM, SWEDEN – April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) annouces that Viktor Drvota today takes over as CEO of the portfolio company Umecrine Cognition. Viktor Drvota remains the CEO of Karolinska Development....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.04.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025
News Preview
STOCKHOLM, SWEDEN – April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition presents recent preclinical data showing that golexanolone reverses dopamine loss and sustains improvements of Parkinsonian symptoms at the 19th International Conference on Alzheimer’s and Parkinson’s D...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.03.2025
KDEV
LISTED
STO
Karolinska Development Annual Report 2024 published
News Preview
STOCKHOLM, SWEDEN – March 21, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.03.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study
News Preview
STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. Due to technical issues in the production of capsules used in the stu...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.03.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01
News Preview
STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an inotropic agent in the EU....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.03.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial
News Preview
STOCKHOLM, SWEDEN – March 12, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug candidate, PN6047, in a pre-IND meeting with the U.S. Food and Drug Administration (FDA). The meeting aimed to provide guidance on the design of the compa...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01
News Preview
STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the GOAL-HF1 clinical study. The study will evaluate AnaCardio’s drug candidate AC01 in patients with heart failure and reduced ejection fraction. Study resu...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
KDEV
LISTED
STO
Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface
News Preview
STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of bacterial growth on the company’s implant surface HAnano Surface. The results are published in the Journal of Functional Biomaterials....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.01.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities
News Preview
STOCKHOLM, SWEDEN – January 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has successfully completed regulatory meetings with the U.S. Food and Drug Administration, FDA, and European Health Agencies, regarding the continued development of the company’s drug candidate tafoxiparin. The...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01
News Preview
STOCKHOLM, SWEDEN January 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has secured SEK 205 million in a series A extension financing round and reports positive results from the first part of a Phase 1b/2a study of AC01 in patients with heart failure and reduced ejection fraction. T...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.12.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone
News Preview
STOCKHOLM, SWEDEN – December 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 23.8 million through a convertible loan to be used for the continuation of the company’s clinical study of golexanolone in primary biliary cholangitis. The convertible loan with attac...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.12.2024
KDEV
LISTED
STO
Karolinska Development’s Board of Directors appoints Ben Toogood as new Chairman
News Preview
STOCKHOLM, SWEDEN – December 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company’s Board of Directors has appointed Ben Toogood as new Chairman until the next General Meeting....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia
News Preview
STOCKHOLM, SWEDEN – December 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in a phase 2 clinical study of the drug candidate sevuparin, evaluated as a treatment for chronic kidney disease with anemia. The study is being conducted at Centro Rice...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
KDEV
LISTED
STO
Karolinska Development implements organizational changes for more efficient portfolio management
News Preview
STOCKHOLM, SWEDEN – December 2, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company has decided to implement organizational changes in order to reduce the cost base of its operations. The changes involve reducing the management team by one person and giving notice of redundancy to a total of three employees. Th...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.11.2024
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics secures bridge financing
News Preview
STOCKHOLM, SWEDEN November 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has secured access to bridge financing of up to SEK 5 million from Karolinska Development, the company’s largest shareholder. The funding enables Modus to initiate the recently approved phase 2a study...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study
News Preview
STOCKHOLM, SWEDEN – November 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present data from a recent interim analysis from an ongoing Phase 1b/2a clinical study of golexanolone in patients with Primary Biliary Cholangitis. The preliminary results show that golexanolo...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
KDEV
LISTED
STO
Karolinska Development's portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO
News Preview
STOCKHOLM, Sweden, 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from today, Friday November 15th, as Dr Richard Bethell has decided to step down as CEO to pursue other professional in...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
KDEV
LISTED
STO
Interim Report - January-September 2024
News Preview
STOCKHOLM – 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-September 2024. The full report is available on the Company's website....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2024
KDEV
LISTED
STO
Karolinska Development’s Extraordinary General Meeting 2024
News Preview
STOCKHOLM, SWEDEN – November 13, 2024. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held an Extraordinary General Meeting on November 13, 2024, at which the shareholders resolved as follows....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company BOOST Pharma successfully completes pre-IND meeting with FDA and receives second tranche of investment
News Preview
STOCKHOLM, SWEDEN, November 5 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has succesfully completed a pre-IND meeting with the U.S. Food and Drug Administration, FDA, for its cell therapy aiming to treat children with the rare bone disease Osteogenesis Imperfecta (OI). The positiv...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition presents new preclinical Parkinson’s data on golexanolone at the scientific conference, INBC 2024
News Preview
STOCKHOLM, SWEDEN – October 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present new preclinical data on golexanolone, showing retained dopamine signalling in Parkinson’s disease, at the 10th International Conference on Neurology and Brain Disorders 2024 in Baltimore...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2024
KDEV
LISTED
STO
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
News Preview
The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting (“EGM”), on Wednesday, November 13, 2024, at 11:00 (CET), at Cirio Law Firm, Biblioteksgatan 9, in Stockholm. Registration for the EGM will commence at 10:30 (CET)....
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
KDEV
LISTED
STO
Karolinska Development divests its holding in the Danish dermatology company Henlez
News Preview
STOCKHOLM, SWEDEN, September 23 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces the divestment of all its shares in the portfolio company Henlez ApS. Following the transaction, Karolinska Development's investment portfolio consists of eleven holdings....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01
News Preview
STOCKHOLM, SWEDEN September 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed the AC01-FE study in the US and also completed the first part of the clinical phase 1b/2a study GOAL-HF1, evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2024
KDEV
LISTED
STO
Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease
News Preview
STOCKHOLM, SWEDEN, September 17 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented positive top-line results from a clinical Phase 1/2 study with a potential first-in-class treatment of the rare bone disease osteogenesis imperfecta (OI). The results show that the treatment...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005
News Preview
STOCKHOLM, Sweden, August 30 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has treated the first patient with the drug candidate BSG005 in the ongoing clinical trial in India. The treatment of the patient, who was diagnosed with mucormycosis (black fungus), proved to be very successful...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
KDEV
LISTED
STO
Interim Report - January-June 2024
News Preview
STOCKHOLM – 30 August 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2024. The full report is available on the Company's website....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.07.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator
News Preview
STOCKHOLM, SWEDEN – July 16, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo has been granted funding of EUR 17.5 million from the European Innovation Council (EIC) Accelerator, a part of the Horizon Europe innovation support program. The funding consists of a grant of EUR 2.5 million and co...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.07.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone
News Preview
STOCKHOLM, SWEDEN – July 10, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has conducted a capital raise, implemented as a convertible loan with attached share options,for the continued development of its drug candidate golexanolone. Karolinska Development participates as part...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection
News Preview
STOCKHOLM, Sweden, June 12 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has received the final permission required to test its lead candidate drug BSG005 in patients with invasive fungal infections in India....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
KDEV
LISTED
STO
Karolinska Development invests in BOOST Pharma, expanding its portfolio
News Preview
STOCKHOLM, SWEDEN – May 28, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the company has invested in BOOST Pharma – a company based on research from Karolinska Institutet that develops a first-in-class and potentially groundbreaking cell-based treatment of the rare bone disease osteogenesis imperfecta, also known as...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2024
KDEV
LISTED
STO
Karolinska Development’s Annual General Meeting 2024
News Preview
STOCKHOLM, SWEDEN – May 16, 2024. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 16, 2024. The shareholders have had the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the articles of association. Therefore, shareholders have had the...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC
News Preview
STOCKHOLM, SWEDEN – May 8, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has randomized its first two patients to the second part of the ongoing clinical phase 1b/2 study of golexanolone in patients with Primary Biliary Cholangitis, PBC. Top-line results are expected in first...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
